Table 6.
Comparison of genotype frequencies of SNPs in the TLR2 gene between ER +ve Saudi BC cases and healthy controls
| Gene | SNP ID | Genotype | Breast, n (%) | Controls, n (%) | OR | 95% CI | χ2-value | P-value |
|---|---|---|---|---|---|---|---|---|
| TLR2 | rs3804100 | n=75 | n=146 | |||||
| CC | 1 (0.01) | 4 (0.03) | Ref | |||||
| CT | 15 (0.2) | 27 (0.18) | 3.000 | 0.303–29.663 | 0.95 | 0.32911 | ||
| TT | 59 (0.79) | 115 (0.79) | 2.682 | 0.292–24.593 | 0.82 | 0.36500 | ||
| CT + TT | 74 (0.99) | 142 (0.97) | 2.741 | 0.300–25.013 | 0.86 | 0.35244 | ||
| C | 17 (0.11) | 35 (0.12) | Ref | |||||
| T | 133 (0.89) | 257 (0.88) | 1.118 | 0.588–2.123 | 0.12 | 0.73393 | ||
| rs4696480 | n=75 | n=138 | OR | 95% CI | χ2-value | P-value | ||
| AA | 16 (0.21) | 25 (0.18) | Ref | |||||
| AT | 34 (0.45) | 63 (0.46) | 0.930 | 0.424–2.038 | 0.03 | 0.85552 | ||
| TT | 25 (0.34) | 50 (0.36) | 0.800 | 0.353–1.815 | 0.28 | 0.59361 | ||
| AT + TT | 59 (0.79) | 113 (0.82) | 0.870 | 0.420–1.804 | 0.14 | 0.70813 | ||
| A | 66 (0.44) | 113 (0.41) | Ref | |||||
| T | 84 (0.56) | 163 (0.59) | 0.881 | 0.579–1.341 | 0.35 | 0.55444 | ||
| rs3804099 | n=75 | n=146 | OR | 95% CI | χ2-value | P-value | ||
| CC | 21 (0.28) | 42 (0.29) | Ref | |||||
| CT | 36 (0.48) | 71 (0.49) | 1.121 | 0.562–2.235 | 0.11 | 0.74589 | ||
| TT | 18 (0.24) | 33 (0.22) | 1.121 | 0.498–2.521 | 0.08 | 0.78258 | ||
| CT + TT | 54 (0.72) | 104 (0.71) | 1.121 | 0.588–2.137 | 0.12 | 0.72880 | ||
| C | 78 (0.52) | 155 (0.53) | Ref | |||||
| T | 72 (0.48) | 137 (0.47) | 1.065 | 0.704–1.612 | 0.09 | 0.76539 |
Abbreviations: SNP, single-nucleotide polymorphism; TLR2, Toll-like receptor 2; ER, estrogen receptor; BC, breast cancer; OR, odds ratio; CI, confidence interval; Ref, reference.